W Helbig

889 total citations
30 papers, 423 citations indexed

About

W Helbig is a scholar working on Hematology, Pathology and Forensic Medicine and Genetics. According to data from OpenAlex, W Helbig has authored 30 papers receiving a total of 423 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Hematology, 7 papers in Pathology and Forensic Medicine and 5 papers in Genetics. Recurrent topics in W Helbig's work include Hematopoietic Stem Cell Transplantation (10 papers), Acute Myeloid Leukemia Research (8 papers) and Hematological disorders and diagnostics (5 papers). W Helbig is often cited by papers focused on Hematopoietic Stem Cell Transplantation (10 papers), Acute Myeloid Leukemia Research (8 papers) and Hematological disorders and diagnostics (5 papers). W Helbig collaborates with scholars based in Germany, United States and Netherlands. W Helbig's co-authors include Gale Rp, RC Ash, N Jacobsen, Olle Ringdén, GL Phillips, AA Rimm, K Atkinson, J. C. Biggs, MM Horowitz and Mathias Freund and has published in prestigious journals such as Blood, British Journal of Haematology and Advances in experimental medicine and biology.

In The Last Decade

W Helbig

26 papers receiving 404 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
W Helbig Germany 8 309 155 86 69 60 30 423
R Cerri Italy 13 387 1.3× 144 0.9× 153 1.8× 125 1.8× 123 2.0× 32 517
Susan R. Wiersma United States 13 260 0.8× 175 1.1× 78 0.9× 75 1.1× 137 2.3× 16 517
H-S Chi South Korea 11 476 1.5× 217 1.4× 117 1.4× 83 1.2× 38 0.6× 15 541
JF Tomás Spain 9 283 0.9× 63 0.4× 94 1.1× 96 1.4× 44 0.7× 17 367
ME Nesbit United States 8 429 1.4× 147 0.9× 127 1.5× 91 1.3× 50 0.8× 12 490
E. P. Alessandrino Italy 11 345 1.1× 96 0.6× 120 1.4× 110 1.6× 115 1.9× 26 505
M Saitta Italy 11 163 0.5× 127 0.8× 38 0.4× 73 1.1× 65 1.1× 20 345
A Molina United States 8 214 0.7× 87 0.6× 120 1.4× 45 0.7× 33 0.6× 19 330
Hasan S. Khalidi United States 10 178 0.6× 113 0.7× 85 1.0× 79 1.1× 49 0.8× 11 332
Vico Vecchi Italy 12 127 0.4× 166 1.1× 71 0.8× 63 0.9× 74 1.2× 28 417

Countries citing papers authored by W Helbig

Since Specialization
Citations

This map shows the geographic impact of W Helbig's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by W Helbig with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites W Helbig more than expected).

Fields of papers citing papers by W Helbig

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by W Helbig. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by W Helbig. The network helps show where W Helbig may publish in the future.

Co-authorship network of co-authors of W Helbig

This figure shows the co-authorship network connecting the top 25 collaborators of W Helbig. A scholar is included among the top collaborators of W Helbig based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with W Helbig. W Helbig is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Herold, Michael, Gottfried Dölken, F. Fiedler, et al.. (2003). Randomized phase III study for the treatment of advanced indolent non-Hodgkin's lymphomas (NHL) and mantle cell lymphoma: chemotherapy versus chemotherapy plus rituximab. Annals of Hematology. 82(2). 77–79. 43 indexed citations
2.
Wolff, Daniel, Frank Reichenberger, Beate Steiner, et al.. (2002). Progressive interstitial fibrosis of the lung in sclerodermoid chronic graft-versus-host disease. Bone Marrow Transplantation. 29(4). 357–360. 27 indexed citations
3.
Hasenclever, Dirk, Rainer Krahl, Wolfram Pönisch, et al.. (2002). Intermediate-dose Cytarabine Treatment Delivered at Moderate Infusion Rates for De Novo Acute Myeloid Leukemia-Results of a phase I-II Study. Leukemia & lymphoma. 43(2). 265–274. 6 indexed citations
4.
Köhler, Thomas, Sabine Leiblein, Dirk Laßner, et al.. (1999). Absolute Levels of MDR-1, MRP, and BCL-2 MRNA and Tumor Remission in Acute Leukemia. Advances in experimental medicine and biology. 457. 177–185. 9 indexed citations
5.
Köhler, Thomas, et al.. (1998). Mechanisms responsible for therapy resistance of acute myelogenous leukemia (AML).. PubMed. 36(2). 97–8. 1 indexed citations
6.
Wolff, Daniel, Cornelia Becker, Wolfram Pönisch, et al.. (1998). Second unrelated bone marrow transplantation without additional conditioning therapy after engraftment failure. Bone Marrow Transplantation. 21(3). 315–317. 8 indexed citations
7.
Egger, Dietmar, Christine Günther, W Helbig, & E. Schulze. (1998). Pre‐treatment of peripheral blood progenitor cells with macrophage inflammatory protein‐1α induces prolonged survival of early progenitor cells over 6 weeks of long‐term culture. British Journal of Haematology. 103(4). 1181–1183.
8.
Biggs, J. C., MM Horowitz, Gale Rp, et al.. (1992). Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy. Blood. 80(4). 1090–1093. 157 indexed citations
9.
Krahl, Rainer, et al.. (1990). Dose-reduced induction therapy for acute leukaemias decreases both the complete remission (CR) rate and the probability of leukaemia-free survival (LFS).. PubMed. 117(6). 783–6. 1 indexed citations
10.
Leiblein, Sabine, et al.. (1989). Immune recovery following bone marrow transplantation.. PubMed. 116(3-4). 509–18. 6 indexed citations
11.
Feyer, Petra, et al.. (1989). Acute and late effects in the course of and after total body irradiation with following bone marrow transplantation in patients with different forms of leukaemia.. PubMed. 116(3-4). 487–91. 4 indexed citations
12.
Gorin, NC, P Hervé, Philippe Aegerter, et al.. (1986). Autologous bone marrow transplantation for acute leukaemia in remission. British Journal of Haematology. 64(2). 385–395. 54 indexed citations
13.
Hammer, Peter E., et al.. (1982). [Thrombocyte substitution in acute leukemia. Effect of histocompatibility on the clinical efficacy].. PubMed. 109(2). 355–64. 1 indexed citations
14.
Helbig, W, et al.. (1982). [Prognostic significance of histobiopsy findings in bone marrow of malignant lymphomas in adults].. PubMed. 37(15). 491–7.
15.
Helbig, W. (1980). [Importance of paraneoplastic bone marrow and blood picture findings].. PubMed. 86. 428–32. 2 indexed citations
16.
Helbig, W, et al.. (1970). [Hematology. Lymphatic and reticulohistocytic system].. PubMed. 112(45). 2057–63. 1 indexed citations
17.
Helbig, W. (1968). Über die Beeinflussung der Fettsäureautoxydation durch Steroide und Steroidderivate. Food / Nahrung. 12(5). 535–548. 3 indexed citations
18.
Helbig, W & Gareth J. Thomas. (1965). [Roentgen findings in lymphogranulomatosis].. PubMed. 20(24). 1077–86.
19.
Helbig, W, et al.. (1963). [On the problem of the syntropy of leukemia and carcinoma].. PubMed. 21(3). 213–20.
20.
Helbig, W & M Weissel. (1961). [Treatment of chronic myelosis with Myleran (myeleukon) with special reference to alkaline leukocyte phosphatase activity].. PubMed. 103. 2390–5. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026